Kast R, Halatsch M, Rosell R
Cells. 2021; 10(5).
PMID: 34068720
PMC: 8151869.
DOI: 10.3390/cells10051148.
Andrade-Neto V, Pacheco J, Inacio J, Almeida-Amaral E, Torres-Santos E, Cunha-Junior E
Front Pharmacol. 2021; 12:636265.
PMID: 33927619
PMC: 8077169.
DOI: 10.3389/fphar.2021.636265.
Iyer P, Schwartz S, Russell J, Flynn Jr H
Case Rep Ophthalmol Med. 2020; 2020:8890404.
PMID: 32855831
PMC: 7443246.
DOI: 10.1155/2020/8890404.
de Denus S, Leclair G, Dube M, St-Jean I, Zada Y, Oussaid E
Eur J Heart Fail. 2020; 22(8):1451-1461.
PMID: 32237012
PMC: 7958586.
DOI: 10.1002/ejhf.1802.
Chiu Y, Zhang Z, Dziemidowicz K, Nikoletopoulos C, Angkawinitwong U, Chen J
Pharmaceutics. 2020; 12(2).
PMID: 32041349
PMC: 7076406.
DOI: 10.3390/pharmaceutics12020139.
Mineralocorticoid receptor antagonism prevents obesity-induced cerebral artery remodeling and reduces white matter injury in rats.
Pires P, McClain J, Hayoz S, Dorrance A
Microcirculation. 2018; 25(5):e12460.
PMID: 29758591
PMC: 6117832.
DOI: 10.1111/micc.12460.
Pannexin Channel Inhibition: An Evolving Target to Lower Blood Pressure?.
Huke S
Circ Res. 2018; 122(4):543-545.
PMID: 29449359
PMC: 5821142.
DOI: 10.1161/CIRCRESAHA.118.312566.
Pannexin 1 Channels as an Unexpected New Target of the Anti-Hypertensive Drug Spironolactone.
Good M, Chiu Y, Poon I, Medina C, Butcher J, Mendu S
Circ Res. 2017; 122(4):606-615.
PMID: 29237722
PMC: 5815904.
DOI: 10.1161/CIRCRESAHA.117.312380.
30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development.
Kolkhof P, Barfacker L
J Endocrinol. 2017; 234(1):T125-T140.
PMID: 28634268
PMC: 5488394.
DOI: 10.1530/JOE-16-0600.
Sexual Reassignment Fails to Prevent Kennedy's Disease.
Lanman T, Bakar D, Badders N, Burke A, Kokkinis A, Shrader J
J Neuromuscul Dis. 2016; 3(1):121-125.
PMID: 27854206
PMC: 10427994.
DOI: 10.3233/JND-150128.
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy.
Badri P, King J, Polepally A, McGovern B, Dutta S, Menon R
Clin Pharmacokinet. 2015; 55(3):275-95.
PMID: 26330025
PMC: 4761011.
DOI: 10.1007/s40262-015-0317-8.
The development of hypertension and hyperaldosteronism in a rodent model of life-long obesity.
Northcott C, Fink G, Garver H, Haywood J, Laimon-Thomson E, McClain J
Endocrinology. 2012; 153(4):1764-73.
PMID: 22355066
PMC: 3320259.
DOI: 10.1210/en.2011-1176.
Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1 + minK channels.
Gomez R, Nunez L, Caballero R, Vaquero M, Tamargo J, Delpon E
Br J Pharmacol. 2005; 146(1):146-61.
PMID: 15980874
PMC: 1576250.
DOI: 10.1038/sj.bjp.0706302.
Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis.
Sica D
Heart Fail Rev. 2005; 10(1):23-9.
PMID: 15947888
DOI: 10.1007/s10741-005-2345-1.
Effects of the aldosterone receptor antagonist potassium canrenoate on renal blood flow and urinary output during prolonged increased intraabdominal pressure (IAP) in pigs.
Gudmundsson F, Viste A, Myking O, Grong K, Svanes K
Surg Endosc. 2005; 18(10):1528-34.
PMID: 15791383
DOI: 10.1007/s00464-003-9295-2.
Suppression of glucocorticoid secretion and antipsychotic drugs have similar effects on the mesolimbic dopaminergic transmission.
Piazza P, Barrot M, Rouge-Pont F, Marinelli M, Maccari S, Abrous D
Proc Natl Acad Sci U S A. 1996; 93(26):15445-50.
PMID: 8986831
PMC: 26424.
DOI: 10.1073/pnas.93.26.15445.
Proceedings of the British Pharmacological Society. 16--18th December, 1980.
Br J Pharmacol. 1981; 73(1):175P-318P.
PMID: 7284696
PMC: 2071855.
DOI: 10.1111/j.1476-5381.1981.tb16787.x.
[On the pharmacokinetics of spironolactone in the elderly].
Abshagen U, Platt D, Horn H
Klin Wochenschr. 1981; 59(16):909-10.
PMID: 7278082
DOI: 10.1007/BF01721925.
Clinical pharmacokinetics of diuretics.
BEERMANN B
Clin Pharmacokinet. 1980; 5(3):221-45.
PMID: 6993083
DOI: 10.2165/00003088-198005030-00003.
The interaction of canrenone with oestrogen and progesterone receptors in human uterine cytosol.
Fernandez M, Carter G, Palmer T
Br J Clin Pharmacol. 1983; 15(1):95-101.
PMID: 6849751
PMC: 1427833.
DOI: 10.1111/j.1365-2125.1983.tb01470.x.
